White House to Spend Billions to Increase Virus Testing and Ease Reopening msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
DiamiR Announces Acquisition of CLIA Lab from Interpace Biosciences
News provided by
Share this article
Share this article
MONMOUTH JUNCTION, N.J., March 17, 2021 /PRNewswire/ DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into a definitive agreement to acquire a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory in New Haven, CT from Interpace Biosciences, Inc. Subject to specific terms and conditions of the agreement being met, it is anticipated that the transaction will close by the end of April, 2021. Financial terms of this transaction have not been disclosed.
The Good Men Project
Become a Premium Member
We have pioneered the largest worldwide conversation about what it means to be a good man in the 21st century.
Your support of our work is inspiring and invaluable.
Have a Case of a COVID Variant? No One Is Going To Tell You
There are arguments for and against notifying patients.
Covid-19 infections from variant strains are quickly spreading across the U.S., but there’s one big problem: Lab officials say they can’t tell patients or their doctors whether someone has been infected by a variant.
Federal rules around who can be told about the variant cases are so confusing that public health officials may merely know the county where a case has emerged but can’t do the kind of investigation and deliver the notifications needed to slow the spread, according to Janet Hamilton, executive director of the Council of State and Territorial Epidemiologists.
March 9, 2021
Wyoming State Veterinary Laboratory technician Morgan Mahlum, a biology major, left, uses a pass-through box to give materials to Amy Rhoad, who loads samples into the robotic testing machine in the UW Biocontainment Facility. Rhoad received her Ph.D. at UW with Associate Professor Kerry Sondgeroth in veterinary sciences. (UW Photo)
The director of the laboratory testing University of Wyoming COVID-19 samples was describing how the Wyoming State Veterinary Laboratory (WSVL) came to be testing 2,500 samples a day when he stopped midsentence and changed facial expressions.
“Let me just step back a minute,” said Will Laegreid, a professor in the Department of Veterinary Sciences.
Message :
Required fields
Positioned as Screening Platform for Efficient Use of Private, State and Federal Next Generation Sequencing (NGS) Resources to Enhance Variant Testing
Newly Developed PCR Panel Detects Specific Mutations to Focus Limited NGS Capacity on Most Impactful Variants of SARS-CoV-2
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced the launch of its Linea™ COVID-19 Selective Genomic Surveillance™ (SGS) Mutation Panel (the “SGS Panel”) to enhance the utility of limited Next Generation Sequencing (NGS) resources in the United States to track better the SARS-CoV-2 Variants of Concern (VOCs) at local, state, and federal levels. The SGS Panel uses a matrix of proprietary quantitative polymerase chain reaction (qPCR) assays that target salient mutations that characterize relevant identified VOCs to narrow the selection of positive samples worth subjecting to NGS